Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
PXD101-301-G
NCT00131261
Last Modified:
12/6/2007
 
First Published:
7/23/2006
2.
Phase II Study of PXD101 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
CCC-PHII-68
7265, NCI-7265, CHNMC-PHII-68, NCT00357032
Last Modified:
5/23/2008
 
First Published:
8/13/2006
3.
Phase II Study of PXD101 as Second-Line Therapy in Patients With Unresectable Malignant Pleural Mesothelioma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Closed
18 and over
NCI
CCC-PHII-67
7255, NCI-7255, NCT00365053
Last Modified:
11/30/2007
 
First Published:
7/14/2006
4.
Phase I Study of PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
WCCC-CO-05906
7277, NCI-7277, NCT00354185
5.
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
18 and over
Pharmaceutical / Industry
PXD101-CLN-4
NCT00413322
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute